Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials

Autor: König, D, Schär, S, Vuong, Diem, Guckenberger, Matthias, Furrer, K, Opitz, I, Weder, W, Rothschild, S I, Ochsenbein, A, Zippelius, A, Addeo, A, Mark, M, Eboulet, E I, Hayoz, S, Thierstein, S, Betticher, D C, Ris, H-B, Stupp, R, Curioni-Fontecedro, A, Peters, S, Pless, M, Früh, M

Publikováno v: König, D; Schär, S; Vuong, D; Guckenberger, M; Furrer, K; Opitz, I; Weder, W; Rothschild, S I; Ochsenbein, A; Zippelius, A; Addeo, A; Mark, M; Eboulet, E I; Hayoz, S; Thierstein, S; Betticher, D C; Ris, H-B; Stupp, R; Curioni-Fontecedro, A; Peters, S; ... (2022). Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. ESMO open, 7(2), p. 100455. Elsevier 10.1016/j.esmoop.2022.100455
ESMO Open

BACKGROUND Chemoradiotherapy with durvalumab consolidation has yielded excellent results in stage III non-small-cell lung cancer (NSCLC). Therefore, it is essential to identify patients who might benefit from a surgical approach. MATERIAL AND METHODS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::440c9860be15495f7a56ae43d495bab4
https://boris.unibe.ch/169233/1/1-s2.0-S2059702922000710-main.pdf

Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]

Autor: König, D, Schär, S, Vuong, Diem, Guckenberger, Matthias, Furrer, K, Opitz, I, Weder, W, Rothschild, S I, Ochsenbein, A, Zippelius, A, Addeo, A, Mark, M, Eboulet, E I, Hayoz, S, Thierstein, S, Betticher, D C, Ris, H-B, Stupp, R, Curioni-Fontecedro, A, Peters, S, Pless, M, Früh, M

Publikováno v: König, D; Schär, S; Vuong, D; Guckenberger, M; Furrer, K; Opitz, I; Weder, W; Rothschild, S I; Ochsenbein, A; Zippelius, A; Addeo, A; Mark, M; Eboulet, E I; Hayoz, S; Thierstein, S; Betticher, D C; Ris, H-B; Stupp, R; Curioni-Fontecedro, A; Peters, S; ... (2022). Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]. ESMO open, 7(3), p. 100494. Elsevier 10.1016/j.esmoop.2022.100494

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b7758c5e0f3b2ce34c3c65c55ccb36d

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.